Pharmaceuticals by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceuticals ranked by P/E ratio, at 5.0, followed by Alnylam Pharmaceuticals (7.8) and Novo Nordisk (10.1). Figures as of 18 Nov 2026, 14:30 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics5.0
- Median
- 40.2
- Combined market value
- PLN 20.62T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 5.0 | PLN 18.5B | PLN 168.91 | 3.75% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.8 | PLN 83.4B | PLN 622.78 | 0.96% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.1 | PLN 711.2B | PLN 161.36 | 1.34% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.4 | PLN 23.6B | PLN 34.67 | 1.15% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.5 | PLN 499B | PLN 244.13 | 1.01% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.0 | PLN 134.4B | PLN 330.78 | 1.38% down | 29% down | ||
| 7 | GSKGSK · Health Care | 17.1 | PLN 394.4B | PLN 196.74 | 0.53% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.7 | PLN 70.9B | PLN 1,080.91 | 0.80% down | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 21.2 | PLN 398.1B | PLN 3,848.23 | 0.56% up | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 22.0 | PLN 100B | PLN 2,346.88 | 0.64% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.6 | PLN 457.3B | PLN 190.45 | 0.27% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.4 | PLN 1.12T | PLN 722.83 | 1.27% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.4 | PLN 32.7B | PLN 500.92 | 0.13% down | 46% up | ||
| 14 | NovartisNVS · Health Care | 30.0 | PLN 1.19T | PLN 631.14 | 1.31% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.4 | PLN 544.2B | PLN 2,146.39 | 0.67% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 39.1 | PLN 728.7B | PLN 420.72 | 2.55% down | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.2 | PLN 644.5B | PLN 113.07 | 1.12% down | 14% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.1 | PLN 49.5B | PLN 59.43 | 0.61% up | 5% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.9 | PLN 2.67T | PLN 1,110.30 | 0.89% down | 38% up | ||
| 20 | GenmabGMAB · Health Care | 44.1 | PLN 127.9B | PLN 207.41 | 0.65% down | 70% up | ||
| 21 | Royalty PharmaRPRX · Health Care | 44.9 | PLN 158.7B | PLN 275.95 | 0.23% up | 78% up | ||
| 22 | Eli LillyLLY · Health Care | 45.9 | PLN 5.07T | PLN 5,687.61 | 1.13% down | 35% up | ||
| 23 | AbbVieABBV · Health Care | 49.8 | PLN 2.06T | PLN 1,164.08 | 1.07% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 52.7 | PLN 30.8B | PLN 281.54 | 1.23% up | 8% down | ||
| 25 | Amneal PharmaceuticalsAMRX · Health Care | 52.8 | PLN 29.6B | PLN 84.86 | 0.52% down | 83% up | ||
| 26 | BeOne MedicinesONC · Health Care | 53.0 | PLN 189.7B | PLN 1,660.46 | 0.48% up | 17% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 71.1 | PLN 62B | PLN 965.67 | 0.15% down | 37% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.1 | PLN 30B | PLN 382.15 | 0.93% up | 126% up | ||
| 29 | TG TherapeuticsTGTX · Health Care | 93.6 | PLN 38.1B | PLN 251.97 | 0.08% down | 107% up | ||
| 30 | Teva Pharmaceutical IndustriesTEVA · Health Care | 99.5 | PLN 200.5B | PLN 171.85 | 0.38% up | 74% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 118 | PLN 23.7B | PLN 1,185.30 | 0.41% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 145 | PLN 1.42T | PLN 576.05 | 0.75% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 309 | PLN 277.8B | PLN 86.95 | 0.23% up | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0179 PLN). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceuticals have the lowest P/E ratio?
Edgewise Therapeutics (5.0), Alnylam Pharmaceuticals (7.8) and Novo Nordisk (10.1) have the lowest P/E ratio of the 33 pharmaceuticals ranked here as of 18 Nov 2026, 14:30 UTC.
How many pharmaceuticals are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 33 pharmaceuticals ranked by P/E ratio have a combined market value of PLN 20.62T as of 18 Nov 2026, 14:30 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceuticals by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.